Table 2.
NGS-based molecular characterization of SARIFA-positive/negative CRCs.
| Gene | Mutational Status: wt/mut |
SARIFA-Positive n = 15 * |
SARIFA-Negative n = 23 * |
p-Value |
|---|---|---|---|---|
| KRAS | wt | 6 (40.0%) | 13 (56.5%) | ns |
| mut | 9 (60.0%) | 10 (43.5%) | ||
| BRAF | wt | 14 (93.3%) | 18 (78.3%) | ns |
| mut | 1 (6.7%) | 5 (21.7%) | ||
| NRAS | wt | 14 (93.3%) | 22 (95.7%) | ns |
| mut | 1 (6.7%) | 1 (4.3%) | ||
| PIK3CA | wt | 11 (73.3%) | 18 (78.3%) | ns |
| mut | 4 (26.7%) | 5 (21.7%) | ||
| CTNNB1 | wt | 15 (100%) | 22 (95.7%) | ns |
| mut | 0 (0%) | 1 (4.3%) | ||
| FGFR1 | wt | 15 (100%) | 22 (95.7%) | ns |
| mut | 0 (0%) | 1 (4.3%) | ||
| FGFR3 | wt | 15 (100%) | 22 (95.7%) | ns |
| mut | 0 (0%) | 1 (4.3%) | ||
| ERBB2 | wt | 15 (100%) | 22 (95.7%) | ns |
| mut | 0 (0%) | 1 (4.3%) | ||
| MET | wt | 15 (100%) | 22 (95.7%) | ns |
| mut | 0 (0%) | 1 (4.3%) | ||
| AKT1 | wt | 15 (100%) | 22 (95.7%) | ns |
| mut | 0 (0%) | 1 (4.3%) |
ns = not significant (p < 0.05); mutational status: mut = mutant; wt = wildtype. * NGS-based multigene testing was possible in 38 of 45 (84.4%) cases of the entire cohort: in 15 of 15 (100%) SARIFA-positive CRCs, and in 23 of 30 (76.7%) SARIFA-positive CRCS.